Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioArctic AB

www.bioarctic.se

Latest From BioArctic AB

Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis

As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period… 

BAN2401 Results Validate Eisai/Biogen's Faith In Alzheimer's Amyloid Tack

In the wake of multiple recent drug failures in the Alzheimer's sector, Eisai and partner Biogen announce "impressive" top-line results for an amyloid-targeting antibody that provide important support for the amyloid hypothesis and may also bode well for the companies' lead candidate in the same class.

Clinical Trials Neurology

Deals Shaping the Medical Industry, October 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2016.

Deals BioPharmaceutical

Eisai Steps Well ‘Beyond The Pill’ In New Japan Care Service

Japanese major Eisai is working with a communications company for a new online system in Japan that will more closely link chronic disease patients and medical care providers, with a number of expected benefits including treatment compliance that could potentially help stem sales declines for two mainstay products.

Commercial Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • BioArctic Neuroscience AB
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • BioArctic AB
  • Senior Management
  • Gunilla Osswald, CEO
  • Contact Info
  • BioArctic AB
    Phone: (46) (0)8-6956931
    Warfvinges väg 35
    Stockholm, SE-112 51
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register